KAPL Search   GO

SWACHHA BHARAT ABHIYAN MESSAGE
Corporate Info
Manufacturing Facilities
Domestic Marketing
International Marketing
Company News
Doctor's Section
Products Ready Recknor
Feedback
Enquiries
Current Job Openings
Grievance Cell - Department of Pharmaceuticals
Application form for employment
Vigilance
Tenders
MSME Procurements
RTI
Back Home


DOCTOR'S SECTION  » Therapeutic Index

APIFEAST™ SYP

The Real Feast Among Appetizers

D E S C R I P T I O N / M O D E O F A C T I O N

APIFEAST is a complete & comprehensive appetizer with Picrorhiza kurroa a potent hepatoprotective agent. Embelia ribes with anthelmintic and anti-inflammatory properties. Cyperus rotundus being an astringent, appetizer, stomachic, anthelmintic and useful in treatment of leprosy, dysentery, pruritis, etc., Emblica Officinalis is highly nutritious and is an important dietary source of vitamin C, minerals and amino acids. Zingiber officinale is a potent digestive aid, prevents nausea, motion sickness & reduces cholesterol. Punica granatum having most notably antioxidant activity. Mentha piperata offers aromatic, stimulant, stomachic and carminative properties. Anethum foeniculum having antiseptic, anti-spasmodic, carminative, depurative, diuretic, emmenagogue, expectorant, galactagogue, splenic, stomachic properties. Vitis vinifera having flavonoids, which has antioxidant effects, lowers low density lipoproteins levels, relaxes blood vessels, and reduces the risk of coronary heart disease. Piper longum a very good carminative and a digestive known as ‘Triphala’ - which is useful in treating respiratory diseases, hypertension, hiccups and topical inflammation. All the above therapeutic benefits make APIFEAST a very comprehensive and natural Appetizer for the entire family.

C O M P O S I T I O N

Each 5ml contains : Qty. in mg
PICRORHIZA KURROA 30mg
EMBELLIA RIBES 20mg
CYPERUS ROTUNDUS 20mg
PIPER LONGUM 30mg
EMBLICA OFFICINALIS 100mg
ZINGIBER OFFICINALE 50mg
PUNICA GRANATUM 100mg
VITIS VINIFERA 30mg
ANETHUM FOENICULUM 50mg
MENTHA PIPERATA 50mg


I N D I C AT I O N S

APIFEAST is indicated in Anorexia [Loss of Appetite].

D O S A G E

Dosage is 2-3 Teaspoonfuls daily or as directed by the physician

S I D E E F F E C T S

No untoward side effects are noticed.

P R E S E N TAT I O N & PACK

APIFEAST is available as 200ml pack.

Antaf ™

An ulcer healing and antiflatulent agent

D E S C R I P T I O N / M O D E O F A C T I O N

Antaf is an excellent ayurvedic antiulcer and antiflatulent agent. Antaf neutralises acid and over comes flatulence. Antaf heals gastric and duodenal ulcer. It gives relief from abdominal discomfort and epigastric pain. Provides immediate relief from heart burn, sour erructations, constipation, nausea and vomiting. Action of Antaf is sustained.

C O M P O S I T I O N

Each tablet contains extracts equivalent to : Qty. in mg
Glycyrrhiza glabra (Yashtimadhu) 150
Embelica officinalis (Amalaki) 150
Narikela lavana 100
Shankha bhasma 100


I N D I C AT I O N S

Antaf is indicated in hyperacidity, gastric and duodenal ulcer.

D O S A G E

2 tablets tid or as directed by the physician

S I D E E F F E C T S

No untoward side effects are noticed.

P R E S E N TAT I O N & PACK

Container of 30’s tablet

CEFPAR™ & CEFPAR - SB™

THE PROVEN POWER OF ANTIMICROBIAL AGENT / SYNERGY

D E S C R I P T I O N / M O D E O F A C T I O N

CEFPAR is only Cefoperazone sodium whereas CERPAR – SB is a combination of Cefoperazone sodium and Sulbactam sodium (1:1). Both exhibit a broad spectrum of antimicrobial activity on Gram negative, Gram positive and Anaerobic organisms. They are very much useful in emergency cases where other antibiotics are found ineffective because of their high degree of reliability with wider spectrum of activity. Cefpar – SB exhibits antimicrobial synergy and has lower MIC than Cefoperazone alone. Also Sublactam enhances the antibacterial potency of Cefoperazone in Cefpar - SB.

C O M P O S I T I O N

Products Molecule Molecule
Each vial CEFPAR INJ (dry powder for injection) contains : Cefoperazone sodium USP 500mg
Each vial CEFPAR SB-1 INJ (dry powder for injection) contains Cefoperazone sodium USP 500mg Sulbactam sodium USP 500mg
Each vial CEFPAR SB-2 INJ (dry powder for injection) contains : Cefoperazone sodium USP 1gm Sulbactam sodium USP 1gm


I N D I C AT I O N S

Monotherapy : They are indicated for the treatment of the following infections when caused by susceptible organisms – Respiratory tract infections (Upper and Lower), Urinary tract infections (Upper and Lower), Peritonitis, Cholecystitis, Cholangitis, and other Intra abdominal infections, Septicemia, Meningitis, Pelvic inflammatory disease, Endometritis, Gonorrhea and other infections of the Genital tract, Skin and soft tissue infections, Bone and joint infections.
Combination therapy : Because of the broad spectrum of activity of Cefpar – SB, most infections cn be treated adequately with this alone. However, it may be used concomtantly with other antibiotics if such combinations are indicated. If an aminoglycoside is used, renal function shoud be monitored during the course of therapy.

D O S A G E

Cefpar: 1g or 2g every 12 hours in adults and 50 to 200mg / kg daily in children. For neonates aged less than 8 days, the drug shoud not be given more frequently than 12 hourly. The daily dose may be increased to 8g or 300 mg/kg/day in severe infections.
Cefpar – SB: 2g to 4g every 12 hours in adults 40 to 80mg / kg daily in children every 6 to 12 hours in equally divided doses. The recommended maximum daily dosage of sulbactam is 4g. For neonates in the first week of life, the drug should be given every 12 hours. The maximum daily dosage of sulbasctam in paediatrics should not exceed 80mg/kg/day. If more than 80mg/kg/day of cefoperazone activity are necessary, additional cefoperazone should be administered seperately.

S I D E E F F E C T S

Contraindications: Known hypersensitivity to cephalosporin class of antibiotics.
Warning: Both CEFPAR & CEFPAR – SB should be administered with caution to any patient who is penicillin sensitive or has demonstrated any other form of allergy, particularly to drugs.
The adverse reactions include allergic reactions, reversible neutropenia, positive direct Coomb’s test, anemia and reduced hematocrit, transient eosinophilia and hypoprothrombinemia have been reported. Transient elevation of SGOT, SGPT, and alkaline phosphatase may occur. Loose stools or diarrhea of mild to moderate severity may occur and is reversible when therapy is terminated. Phlebitis at the site of infusion or transient pain on intramuscular administration may occur in some patients.

P R E S E N TAT I O N & PACK

CEFPAR 500mg / 1g & CEFPAR – SB (1:1) 1g / 2g are presented in vials with unit pack.
CEFPAR – SB (1:1) 1g / 2g are presented in vials with unit pack.

Cetriax™

A high profile once a day criticare injectable antibiotic

D E S C R I P T I O N / M O D E O F A C T I O N

Cetriax is a 3rd generation Cephalosporin with broad spectrum antimicrobial activity. Cetriax cannot be given orally. Usually given intravenously or intramuscularly. It covers most of the gram positive and gram negative organisms. It is highly resistant to betalactamases, including penicillinase and cephalosporinases produced by gram negative and gram positive organisms. Cetriax has 24 hours anti-microbial action by inhibiting cell wall synthesis by breaking down peptidoglycon ring. Plasma concentration achieved by Cetriax is more than MIC required. MIC is less than 8 mcg / ml for most organisms. Peak plasma concentrations are reached within 30 minutes. Cetriax is widely distributed in various tissues and body fluids. High levels are detected in respiratory tract, bone and joints, urinary tract, skin and abdominal organs. It readily enters CSF especially across inflamed meninges. Cetriax also penetrates into vitreous humour. Cetriax crosses the placenta and is excreted in breast milk. Cetriax is not metabolised in the body and has dual excretion by kidneys and rest is secreted into the bile and excreted in the feaces. Plasma protein binding averages between 85 - 95%. Elimination half life is 5.8 - 8.7 hours. Cetriax has the longest half-life among Cephalosporins.

C O M P O S I T I O N

Each vial of Cetriax contains : 250 mg or 1 gm of Sterile Ceftriaxone sodium.

I N D I C AT I O N S

I N D I C AT I O N S
Bacterial meningitis Bacterial septicemia
Surgical prophylaxis Sexually transmitted diseases
Respiratory tract infections Urinary tract infections
Serious skin and soft tissue infections Pelvic inflammatory diseases
Infective endocarditis Osteomyelitis
Enteric Fever Abdominal Sepsis


D O S A G E

Adults : The usual dose is 1 to 2 gm given once a day or in 2 eqully divided doses twice a day depending on the type and severity of infection. The total daily dose should not exceed 4 gm. For uncomplicated gonorrhoea, a single IM dose of 250mg is given. For surgical prophylaxis, the recommended dose is 1gm given 1/2 to 2 hours before surgery.
Children : Skin and soft tissue infections, 50 – 75 mg / kg / day given once a day or in 2 equally divided doses in a day. The total dose should not exceed 2 gm. For serious infections other than meningitis, the daily dose is 50 to 75 mg / kg in divided doses every 12 hours. Total daily dose should not be more than 2 gm. For meningitis a daily dose of 100 mg / kg limited to a maximum of 4 gm / day is given in divided doses every 12 hours. No dose modification is needed in patients with renal or hepatic impairment. Cetriax should be continued for at least 3 days after the patient becomes asymptomatic. The usual duration of treatment is at least for 10 days.

S I D E E F F E C T S

Cetriax is generally well tolerated. Rarely it can produce local reactions, like pain, induration and phlebitis, hypersensitivity reactions like rash, pruritus and fever, eversible biliary pseudolithiasis, super infection with candida, pseudomembranous colitis and vaginitis, Haematological abnormalities like eosinophilia, thrombocytosis, leucopenia and neutropenia. Cetriax should not be given to patients who are allergic to penicillins or cephalosporins. In patients with both hepatic and renal dysfunction the dose of Cetriax should not exceed 2 gms/day. In patients with impaired Vitamin K synthesis eg. Malnutrition, chronic liver disease etc., prothrombin time (PT) should be checked. Cetriax has to be given in pregnancy and nursing mothers only if it is very essential. Cetriax should not be given if there is hyperbilirubinaemia.

P R E S E N TAT I O N & PACK

Cetriax 1.0 gm - Vials containing Ceftriaxone Sodium 1 gm with 10 ml sterile water for injection, in a shock proof tray packed in individual carton.
Cetriax 250mg - Vials containing Ceftriaxone Sodium 250 mg with 5 ml sterile water for injection, packed in a separate carton.

Cetriax™ - S / S 375

A high profile once a day criticare injectable antibiotic

D E S C R I P T I O N / M O D E O F A C T I O N

Cetriax is a 3rd generation Cephalosporin with broad spectrum antimicrobial activity. Cetriax cannot be given orally. Usually given intravenously or intramuscularly. It covers most of the gram positive and gram negative organisms. It is highly resistant to betalactamases, including penicillinase and cephalosporinases produced by gram negative and gram positive organisms. Cetriax has 24 hours anti-microbial action by inhibiting cell wall synthesis by breaking down peptidoglycon ring. Plasma concentration achieved by Cetriax is more than MIC required. MIC is less than 8 mcg / ml for most organisms. Peak plasma concentrations are reached within 30 minutes. Cetriax is widely distributed in various tissues and body fluids. High levels are detected in respiratory tract, bone and joints, urinary tract, skin and abdominal organs. It readily enters CSF especially across inflamed meninges. Cetriax also penetrates into vitreous humour. Cetriax crosses the placenta and is excreted in breast milk. Cetriax is not metabolised in the body and has dual excretion by kidneys and rest is secreted into the bile and excreted in the feaces. Plasma protein binding averages between 85 - 95%. Elimination half life is 5.8 - 8.7 hours. Cetriax has the longest half-life among Cephalosporins.
Sulbactum – semisynthetic beta lactumase inhibitor, highly active against class II to IV beta lactamase. It has been combined with extended spectrum penicillins & cephalosporins for use against beta lactumase producing resistant strains.

C O M P O S I T I O N

Products Molecule Molecule
Each vial of Cetriax – S contains : Sterile Ceftriaxone Sodium 1gm Sulbactam Sodium 500mg
Each vial of Cetriax – S 375 contains : Sterile Ceftriaxone Sodium 250mg Sulbactam Sodium 125mg
.

I N D I C AT I O N S

Cetriax™ - S / S 375 is reccommended in :
Bacterial meningitis, Bacterial septicemia,
Surgical prophylaxis, Sexually transmitted diseases,
Respiratory tract infections, Urinary tract infections,
Serious skin and soft tissue infections, Pelvic inflammatory diseases,
Infective endocarditis Osteomyelitis.


D O S A G E

Adults : The usual dose is 1 to 2 gm given once a day or in 2 eqully divided doses twice a day depending on the type and severity of infection. The total daily dose should not exceed 4 gm.
Children : Skin and soft tissue infections, 50 – 75 mg / kg / day given once a day or in 2 equally divided doses in a day. The total dose should not exceed 2 gm. For serious infections other than meningitis, the daily dose is 50 to 75 mg / kg in divided doses every 12 hours. Total daily dose should not be more than 2 gm. For meningitis a daily dose of 100 mg / kg limited to a maximum of 4 gm / day is given in divided doses every 12 hours. No dose modification is needed in patients with renal or hepatic impairment.

S I D E E F F E C T S

Cetriax is generally well tolerated. Rarely it can produce local reactions, like pain, induration and phlebitis, hypersensitivity reactions like rash, pruritus and fever, eversible biliary pseudolithiasis, super infection with candida, pseudomembranous colitis and vaginitis, Haematological abnormalities like eosinophilia, thrombocytosis, leucopenia and neutropenia. Cetriax should not be given to patients who are allergic to penicillins or cephalosporins. In patients with both hepatic and renal dysfunction the dose of Cetriax should not exceed 2 gms/day. In patients with impaired Vitamin K synthesis eg. Malnutrition, chronic liver disease etc., prothrombin time (PT) should be checked. Cetriax has to be given in pregnancy and nursing mothers only if it is very essential. Cetriax should not be given if there is hyperbilirubinaemia.

P R E S E N TAT I O N & PACK

Cetriax 1.0 gm - Vials containing Ceftriaxone Sodium 1 gm with 10 ml sterile water for injection, in a shock proof tray packed in individual carton.
Cetriax 250mg - Vials containing Ceftriaxone Sodium 250 mg with 5 ml sterile water for injection, packed in a separate carton.

Cidogrel™ & Cidogrel – A ™

THE JUST RIGHT ANTIPLATELET

D E S C R I P T I O N / M O D E O F A C T I O N

Cidogrel is only Clopidogrel bifulphate and Cidogrel – A is combination of Clopidogrel bisulphate and Aspirin. Clopidogrel is an inhibitor of platelet aggregation and it becomes active only after hepatic metabolism by P450 – CYP enzyme. The activated metabolite blocks the P2 purinoceptors (purine receptors) located on the surface of platelets. It inhibits the ADP induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GP IIb / IIIa complex. This clopidogrel – sensitive purinoceptor is thought to be linked to adenylyl cyclase. Hence these receptors are also called as P2Y12 receptors. Dose dependent inhibition of platelet aggregation can be seen 2 hours after single oral dose of clopidogrel. It is rapidly aborbed after oral administration and approxmately 50% was excreted in the urine and 46% in the faeces. The elimination half life of the main circulating metabolite was 8 hours with a half life of 11 days. Aspirin did not modify the clopidogrel – mediated inhibition of ADP induced platelet aggegation. Aspirn acts by inhibiting thromboxane A2 which inhibit platelet aggregation.

C O M P O S I T I O N

Products Molecule Molecule
Each film coated tablet of Cidogrel contains : Clopidogrel bisulphate-75mg
Each film coated tablet of Cidogrel-A contains : Clopidogrel bisulphate-75mg Aspirin IP - 75mg
.

I N D I C AT I O N S

Cidogrel and Cidogrel – A are indicated for the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease. It is also indicated in the treatment of unstable angina.
Cidogrel – A is synergistic combination useful in preventing ischemic episodes and for preventing restenosis of stenosed coronaries.

D O S A G E

Cidogrel : Usually 1 tablet given once daily. A loading dose upto 4 tablets may be given in specific cases.
Cidogrel – A : Usually 1 tablet given once daily.

S I D E E F F E C T S

According to CAPRIE study the following were observed – Gastro intestinal : Abdominal pain, dysepsia, gastritis, and constipation. Haemorrhgic : GI haemorrhage, neutropenia / agranulocytosis. Rash & other skindisorders : Skin and appendage disorders. Others include – Syncope, palpitation, hernia, cardiac failure, vomiting, leg cramps, increased hepatic enzymes, anxiety, insomnia, anaemia, skin ulceration, decreased platelets,sinusitis, eczema.

P R E S E N TAT I O N & PACK

Cidogrel and Cidogrel – A are presented in Alu. Strips of 3 X 10’s tablets in carton.

Cyfolac™

The pro-biotic rejuvenator

D E S C R I P T I O N / M O D E O F A C T I O N

Cyfolac is a combination of Lactic acid bacillus, Folic acid and Vitamin B12. It is used as an excellent microbiotherapy adjuvant to antibiotic therapy. Lactic acid bacillus has both nutritive and therapeutic value. It restores normal intestinal flora.

C O M P O S I T I O N

Ingredients Cyfolac Cap Cyfolac DT
Lactic acid bacillus 120 million spores 120 million spores
Folic acid 1.5 mg 1.5 mg
Vitamin B12 15 mcg 15 mcg


I N D I C AT I O N S

Cyfolac is indicated as an adjuvant with antibiotics and anti- diarrhoeals, in habitual constipation, dyspepsia, vomiting, flatulence, stomatitis, glossitis and gingivitis. It is an excellent supplement in infantile diarrhoea and gastrointestinal disorders in children.

D O S A G E

The recommended dosage : 10 million spores / kg body weight. Usually 1 capsule / tablet thrice daily.
Infants : 50 million spores 3 times a day.
Children: : 50 to 100 million spores 3 times a day.
Adults : 100 to 200 million spores 3 times a day.

S I D E E F F E C T S

Cyfolac is generally well tolerated and hyper-sensitivity is rarely seen.

P R E S E N TAT I O N & PACK

Strips of 10 X 10’s caps in blister pack.
Strips of 10 X 10’s blister pack of Cyfolac DT.

Cyfolac™ Forte

A Fruitful Microfloral Formula

D E S C R I P T I O N / M O D E O F A C T I O N

Supplementing probiotics with prebiotics, which are agents that stimulate the growth and / or activity of nonpathogenic bacteria, is more beneficial than administering only probiotics. This combination of probiotics and prebiotics, called synbiotics. Prebiotics may stimulate probiotic bacteria not only to grow, but also to produce compounds beneficial to the host. Their colonic fermentation produces short chain fatty acids [SCFAs] and lactic acid, which is important factors determining the pH of the colonic lumen. Prebiotics also protect the Probiotic bacteria from destruction in stomach acid & bile.

C O M P O S I T I O N

Composition Each Capsule Each Sachet
Lactobacillus acidophilus 0.75 Billion 0.40 Billion
Lactobacillus rhamnosus 0.75 Billion 0.40 Billion
Bifidobacterium longum 0.75 Billion 0.40 Billion
Bifidobacterium bifidum 0.50 Billion 0.25 Billion
Saccharomyces boulardii 0.10 Billion 0.05 Billion
Fructo Oligo Saccharides 100 mg 100 mg


I N D I C AT I O N S

I N D I C AT I O N S Clinical applications of probiotics in GI conditions
Diarrhoeas of various origins Antibiotic associated diarrhoea
Rotavirus diarrhoea Traveler’s diarrhoea
Gastroenteritis Nosocomial diarrhoea
Clostridium difficile diarrhoea HIV/AIDS diarrhoea
Irritable bowel syndrome Inflammatory bowel disease
Lactose intolerance H.pylori infection


D O S A G E

Dosage : The recommended dosage
Adults : 1 – 2 Caps per day
Children : 1 – 2 Sachets per day

S I D E E F F E C T S

Cyfolac Forte is generally well tolerated and hyper-sensitivity is rarely seen.

P R E S E N TAT I O N & PACK

Strips of 10 X 10’s caps in Alu - Alu pack & Sachet of 5 gm pack.

Dycon™

An anti-diarrhoeal and anti-dysenteric agent

D E S C R I P T I O N / M O D E O F A C T I O N

Dycon is an ayurvedic antidiarrhoeal and antidysenteric with specific ingredients. Dycon stops diarrhoea and treats chronic dysentery. Dycon regulates the secretion of digestive system and helps to overcome irritable bowel syndrome. Dycon helps in relieving tenesmus and flatulence.

C O M P O S I T I O N

Composition Each tablet of Dycon contains, extracts equivalent to : Each 5 ml syrup of Dycon contains, extracts equivalent to :
Holarrhena antidysentrica (Kutaja) 200 mg 20 mg
Myristica fragrans (Jatiphala) 10 mg 10 mg
Punica granatum (Dadima) 75 mg 100 mg
Aegle masrmelos (Bilva) 20 mg 40 mg
Zingiber officinale (Sringavera/Shunti) 5 mg 5
Cuminum cyminum (Sweta jeeraka) 10 mg 10 mg


I N D I C AT I O N S

Dycon tablet / syrup are indicated in diarrhoea, dysentery, mixed infections & irritable bowel syndrome.

D O S A G E

Syrup : 2.5 ml – 5 ml t.i.d.
Tablet : 2 tablets t.i.d.

S I D E E F F E C T S

No untoward side effects are noticed.

P R E S E N TAT I O N & PACK

Syrup : Bottle of 100 ml.
Tablet : Container of 30’s.

EXOL™

A Hepatobiliary stimulant

D E S C R I P T I O N / M O D E O F A C T I O N

Exol is an ayurvedic hepatobiliary stimulant. Exol is a comprehensive formula with specific combination in the treatment of hepatic diseases. Exol promotes growth, improves appetite, digestion and ensures better absorption. Exol protects liver from hepatic damage, it helps elliminate hepatotoxins. Exol stimulates and increases the functional effeciency of liver enzymes. Exol promotes hepatocellular repair and regeneration and helps overcome alcohol toxicity on liver.

C O M P O S I T I O N

Exol Tablets or Syrup contains extract equivalent to : Qty. in mg / tab Qty. in mg / 5 ml
Picrorhiza kurroa (Katuki) 40 20
Phyllanthus niruri (Bhoomyamalaki) 75 30
Tecomella undulata (Rohitaka) 50 20
Tephrosia purpurea (Shara punkha) 100 50
Eclipta alba (Bhringaraja) 80 50
Boerrhavia diffusa (Punarnava) 25 20
Azadirachta indica (Nimbea) 30
-

I N D I C AT I O N S

Exol is indicated in jaundice, infective hepatitis, alcoholic hepatitis, cirrhosis of liver and digestive disorders.

D O S A G E

Syrup : Adults – 10 ml t.i.d
: Children – 5 ml t.i.d
Tablet : – 2 tablet t.i.d or 2 tablet o.i.d as health supplement.

S I D E E F F E C T S

No untoward side effects are reported.

P R E S E N TAT I O N & PACK

Syrup – Bottle of 100 ml.
Tablets – Container of 100’s.

Fubac ™

AN ANTI-FUNGAL & ANTI-BACTERIAL AGENT

D E S C R I P T I O N / M O D E O F A C T I O N

Fubac cream is a combination of anti-fungal, anti-bacterial, anti-inflammatory and anti-pruritic agents. The anti-fungal Clotrimazole, anti infective Gentamicin sulphate, anti-pruritic Iodochlorhydroxy quinoline and the anti-inflammatory class III steroid Beclomethasone dipropionate are all complementary to each other. Fubac offers foursome attack in stubborn mixed infections caused by fungi and bacteria, by the powerful synergy caused by the combination of the 4 ingredients.

C O M P O S I T I O N

Composition Strengths
Beclomethasone dipropionate 0.025% w/w
Neomycin sulphate 0.5% w/w

Clotrimazole 1% w/w
Iodochlorhydroxy quinoline 1% w/w


I N D I C AT I O N S

Fubac is specially designed for mixed fungal and bacterial infections like eczematous mycosis, intertrigo, stubborn tinea infections, allergic dermatitis super infected with fungi. The multiple ingredients in fixed dose combination in Fubac make it particularly helpful in mixed fungal bacterial infection which is difficult to diagnose clinically. Clotrimazole in Fubac is a potent anti-fungal agent which is effective not only against tinea infection but also acts against Candida. Hence Fubac is indicated in common infection like Vulvo vaginitis due to Candida encountered in gyneacological practice. Other indications include Impetigo, Furunculosis, Napkin rash, Otitis externa.

D O S A G E

To be applied sparingly 2-3 times daily on the affected area.

S I D E E F F E C T S

Chickenpox, Scabies, Herpes, Acne, Rosacea leg ulcers, Tubercular and viral skin diseases, post vaccination skin eruption, untreated bacterial and fungal infections, perioral dermatitis cah occur after continuous prophylactic use, prolonged or extensive use in pregnancy. Special precaution during withdrawal: As abrupt withdrawal after prolonged therapy may lead to rebound exacerbation of the disease, gradual withdrawal is recommended. Use in children or on face to be limited to 5 days. Growth retardation is observed in some children with prolonged use of potent steroid.

P R E S E N TAT I O N & PACK

Fubac is presented as 10 gm Lami Tube packed in a carton.

GRENIL™

The quicker, safer pain relief in migraine attack

D E S C R I P T I O N / M O D E O F A C T I O N

Grenil is a combination of Domperidone and Paracetamol. Domperidone is a benzimidazole derivative. It is a selective antagonist of the peripheral dopamine D 2 receptors in stomach and acts on chemoreceptor triggerzone (CTZ). After oral administration, Domperidone is absorbed rapidly and almost completely. The peak plasma concentrations reached within 30 minutes are 23 ng / ml after a 10 mg dose and 80 – 102 ng / ml after a 60 mg dose, Domperidone is bound to plasma proteins (91% - 93%). Roughly 1/3 rd of the administered dose is eliminated through the kidney within the first 24 hours. About 10% of the drug is excreted unchanged in faeces. The elimination half-life of Domperidone is 1.5 hours. It has antiemetic and prokinetic properties. Domperidone has no cholinomimetic (acetyl choline like) action at the peripheral muscarinic receptors. Entry of Domperidone into the CNS is poor. Domperidone constricts the lower oesophageal sphincter and relaxes the pyloric sphincter, thereby abolishes nausea, vomiting and alleviates symptoms of postprandial dyspepsia.

Paracetamol is N-acetyl-para aminophenol, has an effective analgesic and antipyretic properties. Paracetamol is rapidly and almost completely absorbed from the gastrointestinal tract. The plasma concentration reaches a peak in 30 to 60 minutes and the half-life in plasma is about 2 hours. Paracetamol is relatively uniformly distributed throughout the body. Plasma protein binding is around 20% to 50%. After therapeutic doses, 90% to 100% of the drug may be recovered in the urine within the first day, primarily after hepatic metabolism.

C O M P O S I T I O N

Composition Qty. in Tab Qty. in Susp / 5 ml
Domperidone 20 mg 5 mg
Paracetamol 500 mg 250 mg


I N D I C AT I O N S

Grenil Tab is reccommended in : Grenil Susp is reccommended in :
Acute migraine attack Pyrexia associated with nausea and vomiting
Tension headache Tension headache
Menstrual & Pre-menstrual cephalalgia Childhood migraine



D O S A G E

The recommended dosage is as follows :
15 Years & above : 1-2 tablets at the onset of attack, subsequently one tablet every 4 hours, if needed, not exceeding 4 tablets per day.
12-15 Years : 1 tablet at the onset of attack, maximum 3 tablets in 24 hours.

S I D E E F F E C T S

Very rarely allergic reactions and skin rashes may occur. In a few isolated cases, Paracetamol may cause meutropenia, thrombocytopenias and pancytopenia. In adults, hepatotoxicity may occur after ingestion of a single dose of 10 to 15 gm Paracetamol, which may cause a potentially fatal hepatic necrosis. Over dosage may be treated with N-acetyl cysteine – 5% solution orally. Domperidone has been well tolerated in most cases. Occasional minor effects include dry mouth, thirst, headache, diarrhoea, nervousness & transient rash. Extra-pyramidal side effects are rare with Domperidone.

P R E S E N TAT I O N & PACK

Tablet : Strips of 10 X 10’s in Blister pack
Susp : Bottle of 60 ml

GRENIL-F™

For a comprehensive relief in Migraine management

D E S C R I P T I O N / M O D E O F A C T I O N

Flunarizine is a selective calcium antagonist. Prevents cellular calcium overload by reducing excessive transmembrane calcium influx. Its mode of action in migraine is unclear, possible mechanisms are inhibition of vasospasm induced by mediators such as serotonin & prostaglandins, inhibition of cellular hypoxia, & improved blood viscosity & erythrocyte deformability. Flunarizine by blocking calcium channels of vascular smooth muscels of the cranial arteries inhibits vasoconstriction of those arteries. This in turn avoids smooth muscle fatigue & subsequent vasodilatation.
Flunarizine is well absorbed from the gut, peak plasma levels are reached within 2-4hrs and reaching steady state at 5-6 weeks. Under goes extensive hepatic metabolism, excreted through faeces via bile. The terminal elimination half life is about 18 days. Plasma protein binding is 99%. Flunarizine crosses blood brain barrier.

C O M P O S I T I O N
Composition Strengths
Flunarizine HCL 5 mg
Flunarizine HCL 10 mg


I N D I C AT I O N S

Grenil F is recommended in :
Prophylaxis of migraine
Prophylaxis of vertigo & vestibular disorders
Prophylaxis of pheripheral & cerebrovascular disorders


D O S A G E

The recommended dosage is as follows :
Adults : 10mg once a day at bedtime.
7-15 Years / <40 kg : 5mg initially & 10mg later, depending on response.

S I D E E F F E C T S

Sedation, fatigue, weight gain / increased appetite
On chronic treatment – Depression (female patients with the history of depressive illness)
Extrapyramidal symptoms (bradykinesia, rigidity , akathisia, orofacial dyskinesia, tremor)
Porphyria
Infrequently reported adverse reaction : heartburn, nausea, gastralgia, insomnia, anxiety, galactorrhoea, dry mouth, muscle ache

P R E S E N TAT I O N & PACK

Grenil - F 5 mg : Strips of 10 X 10’s in Blister pack
Grenil - F 10 mg : Strips of 10 X 10’s in Blister pack

GLIMKAP™

For the Improvement of Quality of life in Type 2 DM

D E S C R I P T I O N / M O D E O F A C T I O N

Glimepiride is a Sulphonylureas, cause hypoglycaemia by stimulating insulin release from pancreatic beta cells. Sulphonylureas also may further increase insulin levels by reducing hepatic metabolism of the hormone. In the initial months of Sulphonylurea treatments, fasting plasma insulin levels and insulin responses to oral glucose challenges are increased. With chronic administration, circulating insulin declines to those that existed before treatment, but despite this reduction in insulin levels, reduced plasma glucose levels are maintained. The explanation for this is not clear, but it may relate to reduced plasma glucose allowing circulating insulin to have more pronounced effects on its target tissues, and to the fact that chronic hyperglycaemia per se impairs insulin secretion (Glucose toxicity)
Sulphonylureas also stimulate release of somatostatin, and they may suppress the secretion of glucagons slightly.
The effects of the Sulphonylureas are initiated by binding to and blocking an ATP-sensitive K+ channel, which has been cloned. The drugs thus resemble physiological secretagogues (e.g., Glucose, Leucine), which also lower the conductance of this channel. Reduced K+ conductance causes membrane depolarisation and influx of Ca2+ through voltage-sensitive Ca2+ channels.

C O M P O S I T I O N

Composition Strengths
Glimepiride 1 mg
Glimepiride 2 mg


I N D I C AT I O N S

Type 2 DM

D O S AG E

The recommended dosage is as follows :
1-2 mg initially, 4mg as maintenance dose, upto a maximum of 8mg per day, before the first meal.

S I D E E F F E C T S

Hypoglycaemic reactions
Coma
Nausea and vomiting
Cholestatic jaundice
Agranulocytosis
Aplastic and hemolytic anaemias
Generalized hypersensitivity reactions, and dermatological reactions.
Some drugs also, displace the Sulphonylureas from binding proteins, thereby increasing the free concentration transiently. These include other Sulfonamides, Clofibrate, Dicumarol, Salicylates, and Phenylbutazone. Ethanol may enhance the action of Sulphonylureas by causing hypoglycaemia.

P R E S E N TAT I O N & PACK

Glimkap 1mg - Strips of 10 X 10’s tablets in Blister pack
Glimkap 2mg - Strips of 10 X 10’s tablets in Blister pack

GLIMKAP™- M1 / M2

For the Improvement of Quality of life in Type 2 DM

D E S C R I P T I O N / M O D E O F A C T I O N

Glimepiride is a Sulphonylureas, cause hypoglycaemia by stimulating insulin release from pancreatic beta cells. Sulphonylureas also may further increase insulin levels by reducing hepatic metabolism of the hormone. They sensitize the target tissues (especially liver) to the action of insulin. This is due to increase in number of insulin receptors and/or a post receptor action—improving translation of receptor activation. It is hypothesized that long-term improvement in carbohydrate tolerance leads to overall lowering of circulating insulin concentration which reverses the down regulation of insulin receptors.

Metformin: It does not cause insulin release, but presence of insulin is essential for its action. Its main actions are suppression of hepatic gluconeogenesis and glucose output from liver. This is the major action responsible for lowering of blood glucose in diabetics. It also enhances insulin-mediated glucose uptake and disposal in skeletal muscle and fat. Insulin resistance exhibited by type-2 diabetics is thus overcome. It Interferes with mitochondrial respiratory chain and promotes peripheral glucose utilization through anaerobic glycolysis.

C O M P O S I T I O N

Products Glimepiride Metformin SR
Glimkap-M1 1mg 500 mg
Glimkap-M2 2 mg 500 mg


I N D I C AT I O N S

Resistant Type 2 DM

D O S A G E

The tablet should be given once daily with meals and should be started at a low dose and dose should be titrated based on the glucose levels. Since it is a sustained release formulation the tablet should not be broken or chewed and dose titration should be done at increments of 1 tablet only.

S I D E E F F E C T S

Glimepiride: Hypoglycaemic reactions, Coma, Nausea, vomiting, flatulence, diarrhoea or constipation, headache and paresthesias are generally mild and infrequent. Hypersensitivity Rashes, photosensitivity, purpura, transient leukopenia, rarely agranulocytosis.

Metformin: Side effects are frequent, but generally not serious. Abdominal pain, anorexia, bloating, nausea, metallic taste, mild diarrhoea and tiredness are the usual complaints, which tend to subside with time. Metformin does not cause hypoglycaemia except in overdose. It rarely causes lactic acidosis and Vit B12 deficiency.

P R E S E N TAT I O N & PACK

Glimkap-M1- Strips of 10 X 10’s tablets in Blister pack
Glimkap-M2- Strips of 10 X 10’s tablets in Blister pack

HUSKY™

A Natural Bowel Facilitator

D E S C R I P T I O N / M O D E O F A C T I O N

The active ingredient in Husky is Psyllium husk (Ispaghulla husk), a natural dietary fiber derived from Plantago ovata seeds. Psyllium husk is neither digested nor absorbed in the small intestine. The bulk forming effect is due to both the water binding capacity of undigested fiber and the increased bacterial mass following partial digestion in the colon. These actions result in distension of the colon and soften stools, thereby decreasing intraluminal pressure, straining and speeding colonic transit in constipated patients. Psyllium binds to bile acids, reducing their intestinal reabsorption and promoting their excretion. The consequent enhancement of hepatic synthesis of bile acids from cholesterol may reduce plasma cholesterol in low-density lipoproteins. With several months of use, bulk forming agents reduce intraluminal rectosigmoid pressure and relieve symptoms in patients with irritable bowel syndrome and diverticular disease of the colon. The capacity of these agents to absorb water makes them useful in relieving the symptoms of mild diarrhoea and for the regulation of effluent in patients with ileostomy or colostomy.

C O M P O S I T I O N

Composition Husky 100 gm Container Husky Sachet
Ispaghulla husk powder (Psyllium husk) 65.00% 65.00%
Sarijka kshar (Sodium bicarbonate) 11.48% 11.48%
Nimbu satwa (Citric acid) 12.22% 12.22%


I N D I C AT I O N S

Husky Container / Sachet is indicated in :
Chronic constipation,
Irritable bowel syndrome,
Haemorrhoids and Fissures,
Hypercholesteraemia & Obesity.


D O S A G E

One teaspoonful once or twice daily along with plenty of water.

S I D E E F F E C T S

Bulk forming laxatives have very few side effects and minimal systemic effect. Allergic reactions may occur but very rarely. Flatulence and Borborygmi occur occasionally. Psyllium husk may contain significant qualities of Na + and should not be used when systemic retention of Na + and H2O is a problem. Psyllium may bind to Coumarin derivatives. Individuals with stenosis, ulceration or adhesions should avoid these agents. Oesophageal and intestinal obstruction can occur when these substances are taken without adequate fluid intake. Patients may avoid these problems by drinking a glass of water concurrently.

P R E S E N TAT I O N & PACK

Husky Granules Available in 100 gm container
Husky Sachet Available in 5 gm sachet.


KAMADOL™

The analgesic answer to severe pain

D E S C R I P T I O N / M O D E O F A C T I O N

Kamadol is Tramadol hydrochloride which is a centrally acting analgesic & an atypical opioid which relieves pain by opioid and non-opioid mechanisms. The analgesic activity of tramadol is due to both parent drug and the M1 metabolite. Tramadol is well absorbed orally with an absolute bioavailability of 75%. It is only 20% bound to plasma proteins and is extensively metabolised. Tramadol and its metabolites are excreted primarily in the urine with observed plasma half lives of 6.3 and 7.4 hours for Tramadol and M1 metabolite. It is rapidly and almost completely absorbed after oral administration. The mean absolute bioavailability of a 100 mg oral dose is approximately 75%. Tramadol is extensively metabolised in the body. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites.

C O M P O S I T I O N

Products Composition Strengths
Kamadol 100 Inj Tramadol Hcl 100mg / 2ml
Kamadol 50 Inj Tramadol Hcl 50mg / 1ml


I N D I C AT I O N S

Tramadol is indicated for the management of moderate to moderately severe pain. It is indicated in Post operative pain due to General, Orthopedic and Gynaecological surgery. Maxillofacial and other Dental surgery. Tramadol is also indicated in Painful bone metastasis, Acute joint pains and Neuropathic pain syndromes.

D O S A G E

Adults : 100 mg o.d. or b.i.d. by I.M. / I.V.
Children : 1 mg / kg body weight by I.M. / I.V.
For the treatment of painful conditions, Tramadol 100 mg can be administered as needed for relief every four to six hours not to exceed 400 mg per day. For moderate pain, 50 mg may be adequate as the initial dose and for more severe pain, 100 mg is usually more effective as the initial dose. For elderly patients over 75 years, not more than 300 mg/day in divided doses as above is recommended.

S I D E E F F E C T S

Respiratory depression [less than opioids], sedation, constipation, urinary retention, dizziness, nausea, sleeptiness, dry mouth, sweating etc are commonly noticed.

P R E S E N TAT I O N & PACK

Kamadol is presented in 2 strengths as -
Kamadol 100 5 X 2 ml Ampoules in a carton.
Kamadol 50 5 X 1 ml Ampoules in a carton.


KAMADOL™- P

For Complete Freedom From Pain

D E S C R I P T I O N / M O D E O F A C T I O N

Tramadol is a centrally acting analgesic structurally related to opioid derivatives like codeine. Tramadol acts at both spinal and supraspinal areas. It acts by two mechanisms.
By inhibiting the neuronal uptake of serotonin and norepinephrine, it reduces pain
By binding to μ opioid receptors it reduces pain.
Thus the effect of tramadol is the sum of both the above actions.

Pharmacikinetics : Tramdol is rapidly and almost completely absorbed after oral administration .
Bioavailability : 75%
Plasma protien binding : 20%
Duration of action : 6 hours
Metabolised by liver and excreted by kidney. M1 metabolite is 6 times as potent as the parent drug. This enhances the duration action. Dose may need to be adjusted in renal / hepatic failure and in very old patients
Paracetamol is a time tested analgesic antipyretic. It has weak activity on prostaglandin synthatase in the peripheral inflamed tissue. However it equals the blocking effect of aspirin on this enzyme in the brain. Therefore paracetamol is a potent antipyretic and is equianalgesic with aspirin in therapeutic doses.
Clinical efficacy : Tramodol and paracetamol in combination is incresingly becoming popular for the treatment of moderate to severe pain. Besides providing good analgesic efficacy this combination improves exercise capability in such patients

C O M P O S I T I O N

Composition Strenghts
Tramadol HCL 37.5 mg
Paracetamol 325 mg


I N D I C AT I O N S

Arthritic pain - ostearthritis, rheumatoid arthritis Diabetic neuropathy,
Trigeminal neuralgia, Post herpetic neuralgia
Pain due to fractures, Disc prolapse
Burns, Sciatica,
Post surgical pain & dental pain Cancer pain.


D O S A G E

Moderate to Severa Pain: 1 – 2 Tablets 3 to 4 times a day.

S I D E E F F E C T S

Common side effects include nausea, vomiting, dry mouth, dizzinesss, headach and sedation.

C O N T R A I N D I C A T I O N S

Known hypersensitivity to any of the ingredients or excipients or opioids.
Acute intoxication with alcohol, hypnotics, opioids, psychoactive substances.
Concurrent intake of monoamine oxidase inhibitors (MAOIs)
Inadequately controlled epilepsy.

P R E S E N TAT I O N & PACK

Kamadol - P: 10 X 10’s Tablets in blister packs.

Kapril™

The Proven ACE inhibitor for risk reduction

D E S C R I P T I O N / M O D E O F A C T I O N

Ramipril and its active metabolite ramiprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. The effect of ramipril on hypertension appears to result at least in part from inhibition of both tissue and circulating ACE activity, thereby reducing angiotensin II formation in tissue and plasma. While the mechanism through which ramipril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, ramipril has an antihypertensive effect even in patients with low-renin hypertension.
The extent of absorption is at least 50-60% and is not significantly influenced by the presence of food in the GI tract. Peak plasma concentrations of ramiprilat are reached 2-4 hours after drug intake. The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%, about 60% of the parent drug and its metabolites are eliminated in the urine, and about 40% is found in the feces.

C O M P O S I T I O N

Kapril 2.5 Tabs Each Tablet contains Ramipril HCL 2.5 mg
Kapril 5 Tabs Each Tablet contains Ramipril HCL 5 mg


I N D I C AT I O N S

Hypertension,
Heart failure,
Myocardial Infarction,
Prophylaxis of cardiovascular events.


D O S A G E

2.5 -10 mg per day, once daily or twice a day in divided doses.

S I D E E F F E C T S

Hypotention, Hyperkalemia, Rashes, Urticaria, Angioedema, Dysgeusia,
Headache, dizziness, fatigue, asthenia, cough and impotence

P R E S E N TAT I O N & PACK

Kapril 2.5 Tablets Blister pack of 10 x 10’s Tablets
Kapril 5 Tablets Blister pack of 10 x 10’s Tablets


Kapril™- H

The synergistic combination for heart failure

D E S C R I P T I O N / M O D E O F A C T I O N

Ramipril and its active metabolite ramiprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. The effect of ramipril on hypertension appears to result at least in part from inhibition of both tissue and circulating ACE activity, thereby reducing angiotensin II formation in tissue and plasma. While the mechanism through which ramipril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, ramipril has an antihypertensive effect even in patients with low-renin hypertension.
The extent of absorption is at least 50-60% and is not significantly influenced by the presence of food in the GI tract. Peak plasma concentrations of ramiprilat are reached 2-4 hours after drug intake. The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%, about 60% of the parent drug and its metabolites are eliminated in the urine, and about 40% is found in the feces.
Hydrochlorothiazide- INHIBITOR OF NA+ -CL- SYMPORT
The mechanism involves increased proximal reabsorption owing to volume depletion, as well as direct effects of thiazides to increase Ca2+ reabsorption in the DCT. In this regard, inhibition of the Na+ -Cl- symporter in the luminal membrane decreases intracellular Na+ levels, thereby increasing the basolateral exit of Ca2+ via enhanced Na+ -Ca2+ exchange . Thiazide diuretics may cause a mild magnesuria by a poorly understood mechanism, and there is increasing awareness that long-term use of thiazide diuretics may cause magnesium deficiency, particularly in the elderly . Since inhibitors of Na+ -Cl- symport inhibit transport in the cortical diluting segment, thiazide diuretics attenuate the ability of the kidney to excrete a dilute urine during water diuresis.
Oral bioavailability- 70%, plasma half life- 2.5h, excreted by renal elimination.

C O M P O S I T I O N

Kapril - H Tabs Each Tablet contains Ramipril HCL 2.5 mg & Hydrochlorothiazide 12.5 mg


I N D I C AT I O N S

Resistant Hypertension
Essential Hypertension
Heart failure
Vascular complications in diabetes


D O S A G E

2.5 -10 mg per day, once daily or twice a day in divided doses.

S I D E E F F E C T S

Hypotention, Hyperkalemia, Rashes, Urticaria, Angioedema, Dysgeusia,
Headache, dizziness, fatigue, asthenia, cough and impotence
Hypokalemia, acute saline depletion, dilutional hyponetremia, hearing loss, hyperuricaemia,

P R E S E N TAT I O N & PACK

Kapril - H: Blister pack of 10 x 10’s Tablets

Lotace™

The Comprehensive Management of Hypertension

D E S C R I P T I O N / M O D E O F A C T I O N

Losartan potassium, the first of a new class of antihypertensives, is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1[p-(o-1H-tetrazol-5-dylphenyl)benzyl]imidazole-5-methanol monopotassium salt. Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II), is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues, (e.g., vascular smooth muscle, adrenal gland). There is also an AT2 receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis. Both losartan and its principal active metabolite do not exhibit any partial agonist activity at the AT1 receptor and have much greater affinity (about 1000-fold) for the AT1 receptor than for the AT2 receptor. The active metabolite is 10 to 40 times more potent by weight than losartan.

C O M P O S I T I O N

Lotace 25 Tabs Each Tablet contains Losartan Potassium 25 mg
Lotace 50 Tabs Each Tablet contains Losartan Potassium 50 mg


I N D I C AT I O N S

Mild to moderate essential hypertension
Cardiac failure
Diabetic nephropathy
Left Verntricular dysfuction
Myocardial infarction


D O S A G E

Lotace 25 / 50 : One tablet once or twice daily

S I D E E F F E C T S

Fetopathic potential – Not to be administered during pregnancy.
Angioedema is reported in few cases, Headache, dizziness, weakness, upper GI side effects are mild.

P R E S E N TAT I O N & PACK

Lotace 25 Tablets Blister pack of 10 x 10’s Tablets
Lotace 50 Tablets Blister pack of 10 x 10’s Tablets


Lotace™ 50 - H

The Composite Management of Hypertension

D E S C R I P T I O N / M O D E O F A C T I O N

Losartan potassium, the first of a new class of antihypertensives, is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1[p-(o-1H-tetrazol-5-dylphenyl)benzyl]imidazole-5-methanol monopotassium salt. Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II), is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues, (e.g., vascular smooth muscle, adrenal gland). There is also an AT2 receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis. Both losartan and its principal active metabolite do not exhibit any partial agonist activity at the AT1 receptor and have much greater affinity (about 1000-fold) for the AT1 receptor than for the AT2 receptor. The active metabolite is 10 to 40 times more potent by weight than losartan.
Hydrochlorothiazide- INHIBITOR OF NA+ -CL- SYMPORT
The mechanism involves increased proximal reabsorption owing to volume depletion, as well as direct effects of thiazides to increase Ca2+ reabsorption in the DCT. In this regard, inhibition of the Na+ -Cl- symporter in the luminal membrane decreases intracellular Na+ levels, thereby increasing the basolateral exit of Ca2+ via enhanced Na+ -Ca2+ exchange . Thiazide diuretics may cause a mild magnesuria by a poorly understood mechanism, and there is increasing awareness that long-term use of thiazide diuretics may cause magnesium deficiency, particularly in the elderly . Since inhibitors of Na+ -Cl- symport inhibit transport in the cortical diluting segment, thiazide diuretics attenuate the ability of the kidney to excrete a dilute urine during water diuresis.
Oral bioavailability- 70%, plasma half life- 2.5h, excreted by renal elimination.

C O M P O S I T I O N

Lotace 50 – H Tablets Each Tablet contains Losartan Potasium 50 mg & Hydrochlorothiazide 12.5 mg



I N D I C AT I O N S

I N D I C AT I O N S
Moderate to severe essential hypertension
Cardiac failure
Diabetic nephropathy
Left Verntricular dysfuction
Myocardial infarction


D O S A G E

Lotace 50 – H : One tablet daily

S I D E E F F E C T S

Fetopathic potential – Not to be administered during pregnancy.
Angioedema is reported in few cases, Headache, dizziness, weakness, upper GI side effects are mild.
Hypokalemia, acute saline depletion, dilutional hyponetremia, hearing loss, hyperuricaemia,

P R E S E N TAT I O N & PACK

Lotace 50 – H: Blister pack of 10 x 10’s Tablets

MAXIFLAM - SP™

The anti inflammatory par excellence with specific advantages

D E S C R I P T I O N / M O D E O F A C T I O N

Maxiflam-SP is a combination of Nimesulide, a sulfanilide compound which is a selective COX2 inhibitor sparing gastroprotective prostaglandins i e COX1, and Serratiopeptidase, a proteolytic enzyme which degrades proteins, reduces inflammation, oedema and hydrolyses bradykinin, histamine and serotonin. These substances cause dilatation of blood vessels. By hydrolysing these substances serratiopeptide indirectly reduces dilation of blood vessels and also blocks plasmin inhibitors, thus helping fibrinolytic activity of plasmin. Degradation of extrafibrin to small fragments prevents clogging of micro capillaries, reduces walling of effects, helps clear exudate, reduces swelling and improves micro-circulation.

C O M P O S I T I O N

Each enteric coated tablet contains Nimesulide 100 mg + Serratiopeptidase 15 mg


I N D I C AT I O N S

Maxiflam - SP provided effective anti-inflammatory care in :
Trauma, injury and post surgical inflammation, Carpal Tunnel syndrome,
Bronchiectasis & bronchitis, Keratitis and Uveitis,
Pericoronitis and Alveolar abscess, Breast engorgement,
Acute and chronic sinusitis, Tonsillectomy, Otitis media,
Periodontites, Lateral episiotomy, Perincal laceration,
Salphingitis, Cystitis, Epidydemitis, Urethritis
Incomplete expectoration of sputum in bronchitis, pulmonary tuberculosis, bronchial asthma.


D O S A G E

The recommended dosage for adults is 1 tablet twice daily and should be taken / swallowed after meal.

S I D E E F F E C T S

Generally, Maxiflam SP is well tolerated. Occasionally it may cause gastro intestinal effects such as anorexia, gastric discomfort and nausea. Hypersensitivity reactions may occur rarely.

DRUG INTERACTIONS

Fenofibrate, Salicylic acid, Valproic acid and Tolbatumide : These drugs displace Nimesulide from the plasma binding sites.
Methotrexate and Frusemide : These drugs may be displaced from plasma proteins by Nimesulide.
Warfarin : Excercise caution since efficacy may be increased.
Theophyllin : Efficacy of slow release theophyllin preparations reduced.

P R E S E N TAT I O N & PACK

Strips of 10 x 10’s uncoated tablets in aluminium foil pack.

Numol™

The most potent dual acting analgesic and anti inflammatory agent

D E S C R I P T I O N / M O D E O F A C T I O N

Numol is an excellent combination of Diclofenac Sodium and Paracetamol. Diclofeanc Sodium is the most potent anti infammatory analgesic and Paracetamol is known to be the safest and effective anti pyretic. Put together, both exert a potent analgesic, anti-inflammatory and anti pyretic effects. Numol attacks pain centrally and fights pain and inflammation peripherally. While both Paracetamol and Diclofenac are known for their proven efficacy a specially designed formulation of Numol has further made it convenient, safe and effective. While Plasma concentration of Paracetamol is achieved in half - an hour, mean plasma concentration for Diclofenac Sodium at 50 mg dose is achieved 0.7 - 1.5 mg / lit. Numol is well absorbed from G.I. tract and is well tolerated.

C O M P O S I T I O N

C O M P O S I T I O N

Each tablet of Numol contains Diclofenac Sodium (enteric coated) 50 mg and Paracetamol (film coated) 325 mg


I N D I C AT I O N S

I N D I C AT I O N S
Aches and pains
Sprains and strains
Soft tissue injury
Dysmenorrhoea
Low back pain
Dental pain
.

D O S A G E

2-3 tablets / day in divided doses for adults

S I D E E F F E C T S

Generally Numol is well tolerated. Very rarely patients may complain of gastric irritation, dyspepsia or ulcers. Hypersensitivity, hepatic damage or haematological cases like agranulocytosis, bone marrow suppression, pancytopenia, aphasia are seen in longterm usage. Likely interactions with antacids, lithium, digoxin. Children under 2 years show decreased metabolism of Numol.

P R E S E N TAT I O N & PACK

Strips of 10x10’s tablets in blister pack

Numol™- A

For Freedom Of Movement In Painful Conditions

D E S C R I P T I O N / M O D E O F A C T I O N

Aceclofenac is a novel NSAID known to exhibit multifactor mechanism of action
vDirectly blocks PGE 2 secretion at the site of inflammation by inhibiting IL-Beta & TNF in the inflammatory cells
vBlocks degeneration and stimulates synthesis of extracellular matrix of cartilages by inhibiting the action of different cytokines.
vInhibit IL-6 production by human chondrocytes.
vSuppression of GAG [Glucosaminoglycan] and collagen synthesis and stimulates growth factor mediated synthesis of GAG and collagen.
vInhibits Neutrophil Adhesion & Accumulation at the inflammatory site in the early phase and thus blocks the pro-inflammatory actions of Neutrophils.
Well absorbed from GIT, peak plasma concentration are reached 1-3 hr, 99% plasma protein bound, Plasma elimination half-life is approximately- 4hrs.

Paracetamol : The plasma elimination half-life ranges from 1 to 4 hours for paracetamol. Paracetamol is distributed throughout most fluids of the body, and is metabolized primarily in the liver. Little unchanged drugs are excreted in the urine, but most metabolic products appear in the urine within 24 hours.

C O M P O S I T I O N

C O M P O S I T I O N
Numol - A Tablets Each Tablet contains Aceclofenac 100mg + Paracetamol 325mg


I N D I C AT I O N S

I N D I C AT I O N S
Osteoarthritis & Rheumatoid arthritis
Ankylosing spondylitis
Post operative & Dental pain
Gonalgia [Pain in the knee]
Lumbago [Low back Pain]
Gynaecological inflammatory conditions
ENT inflammatory conditions
Dysmenorrhoea


D O S A G E

NUMOL – A: 1 – 2 Tabs per day

S I D E E F F E C T S

NUMOL – A is generally well tolerated and has got a superior side effects profile as compared to other NSAIDS. However, it must be used with caution in patients with peptic ulcers, hyper acidity, severe hepatic, cardiac or renal insufficiency. Numol - A can not be used with triametrene and methotrexate and children less than 18 months of age. It is to be used with care in pregnant / lactating women. Leukocytoclastic vasculitis & haemoptysis

P R E S E N TAT I O N & PACK

NUMOL – A Tablet - Strips of 10x10’s in blister packs

Numol™- MR

The Maestro Among Muscle Relaxants

D E S C R I P T I O N / M O D E O F A C T I O N

Aceclofenac is a novel NSAID known to exhibit multifactor mechanism of action
vDirectly blocks PGE 2 secretion at the site of inflammation by inhibiting IL-Beta & TNF in the inflammatory cells
vBlocks degeneration and stimulates synthesis of extracellular matrix of cartilages by inhibiting the action of different cytokines.
vInhibit IL-6 production by human chondrocytes.
vSuppression of GAG [Glucosaminoglycan] and collagen synthesis and stimulates growth factor mediated synthesis of GAG and collagen.
vInhibits Neutrophil Adhesion & Accumulation at the inflammatory site in the early phase and thus blocks the pro-inflammatory actions of Neutrophils.
Well absorbed from GIT, peak plasma concentration are reached 1-3 hr, 99% plasma protein bound, Plasma elimination half-life is approximately- 4hrs.

Thiocolchicoside: Thiocolchicoside is a natural derivative of colchicine & a semi-synthetic derivative of colchicoside. Thiocolchicoside acting as a GABA-A receptor antagonist, its myorelaxant effects could be exerted at the supra-spinal level, via complex regulatory mechanisms, although a glycinergic mechanism of action cannot be excluded.

C O M P O S I T I O N

C O M P O S I T I O N
Numol MR 4 Tablets Each Tablet contains Aceclofenac 100mg + Thiocolchicoside 4mg
Numol MR 8 Tablets Each Tablet contains Aceclofenac 100mg + Thiocolchicoside 8mg


I N D I C AT I O N S

I N D I C AT I O N S

Degenerative vertebral disorders
Torticollis (Wry neck)
Dorsal pain and low back pain
Neurological disorders


D O S A G E

Numol MR 4 – twice a day for 5 to 7 days
Numol MR 8 – once a day for 5 to 7 days

S I D E E F F E C T S

Aceclofenac is generally well tolerated and has got a superior side effects profile as compared to other NSAIDS. However, it must be used with caution in patients with peptic ulcers, hyper acidity, severe hepatic, cardiac or renal insufficiency. Aceclofenac cannot be used with triametrene and methotrexate and children less than 18 months of age. It is to be used with care in pregnant / lactating women. Leukocytoclastic vasculitis & haemoptysis
Side effect of skeletal muscle relaxants may include: sedation, drowsiness, blurred or double vision, constipation or diarrhea, dizziness and drowsiness, nervousness and confusion, dry mouth, dyspepsia (chronic or recurrent pain in the upper abdomen, upper abdominal fullness, and feeling full earlier than expected when eating), fatigue, headache, heartburn, hiccups and nausea, insomnia, stomach cramps, trembling, vomiting, and weakness; and possible dependence following long-term use, Photosensitivity reactions.

P R E S E N T A T I O N & PACK

NUMOL – MR 4mg & 8mg Tablets - Strips of 10x10’s in blister packs

OLIGEL™

Fast acting topical gel for musculoskeletal injuries

D E S C R I P T I O N / M O D E O F A C T I O N

Oleum Lini is a yellowish with peculiar odour and bland taste. It is used as an emollient. Oleum Lini contains predominantly essential fatty acids i.e. -Linolenic anid. On percutaneous absorption -Linolenic acid is converted to Eicosapentanoic acid [EPA]. EPA is acted upon by cyclo-oxygenase enzyme to produce prostaglandin E3 that is a weak inflammatory agent. Presence of EPA prevents the action of cyclo-oxygenase on arachidonic acid, thus reducing its conversion to PGE2 (a highly inflammatory agent).
Methyl salicylate (Oil of Wintergreen) is a colourless or pale yellow or reddish liquid with a strong characteristic aromatic odour. Very slightly soluble in water, soluble in 1 in 7 of alcohol (70%). Methyl salicylate is a known anti-inflammatory agent. Menthol is a colourless, prismatic crystal or crystalline powder with a penetrating odour. Menthol is slightly soluble in water, very soluble in alcohol, chloroform and ether. After absorption, menthol is excreted in the urine and bile as a glucoronide metabolite.

C O M P O S I T I O N

Each Oligel cream contains :
Oleum Lini (Linseed Oil) 3.00% w/w
Diclofenac diethylamine 1.16% w/w
Methyl salicylate 10.00% w/w
Menthol 5.00% w/w


I N D I C AT I O N S

Oligel is indicated for the quick relief from pain, swelling and inflammation due to musculoskeletal disorders such as sprains, strains, tendonitis, bursitis, hand,neck and shoulder pain, sciatica, muscle stiffness, joint pain, back ache and lumbago.

P R E S E N TAT I O N & PACK

Each Oligel cream tube is available as 30 gm, packed in a carton.

Pertenol™

The ‘Perfect – Ten’ Antihypertensive

D E S C R I P T I O N / M O D E O F A C T I O N

Pertenol is Atenolol, a cardio selective adreno receptor blocking agent. Pertenol is an effective and a well tolerated beta blocker having certain distinct advantages, especially in the treatment of hypertension. Pertenol reduces both systolic and diastolic blood pressure. Pertenol is rapidly absorbed from G.I. tract. Pertenol does not undergo first pass hepatic metabolism. Being hydrophyllic, Pertenol is free from disturbing CNS side effects. It is widely distributed in the body. However, only a small portion of Pertenol is excreted in urine unchanged. Pertenol diffuses across the placenta is excreted in breast milk.

C O M P O S I T I O N
C O M P O S I T I O N
Pertenol - 50 Tablets Each scored tablet contains - Atenolol - 50mg


I N D I C AT I O N S

I N D I C AT I O N S
Hypertension
Angina pectoris
Cardiac arrhythmia
Hyperthyroidism
.

D O S A G E

50 – 100 mg once daily or as directed by the physician. Increasing the dose beyond 100 mg a day does not likely to produce any further benefit. In patients with impaired renal function dosage should be individualised on the basis of renal function tests. For those patients whose glomerular filtration rate is between 10 and 30 ml per minute (or serum creatinine is between 2.5 & 5 mg per 100 ml on at least two occasions), 50 mg Pertenol per day is recommended.

S I D E E F F E C T S

Pertenol is generally well tolerated. The common side effects include diarrhoea, fatigue and cold extremities. Vivid dreams and insomnia have reported occasionally. Bronchospasm has been seen in a few patients and therefore, appropriate precaution may be taken.

P R E S E N TAT I O N & PACK

Tablets 50 mg - Strips of 10x14’s scored tablets in blister pack.

Piokap™

FOR EFFECTIVE GLYCAEMIC CONTROL & REVERSAL OF INSULIN RESISTANCE

D E S C R I P T I O N / M O D E O F A C T I O N

Piokap is only Pioglitazone. Pioglitazone belongs to thiazolidinedione group of oral anti-diabetic drugs, that has been developed for the treatment of type 2 diabetes mellitus. It acts by binding with high affinity to and activates the nuclear Peroxisome Proliferator Activated Receptor – Gamma (PPAR- Gamma) - expressed mainly in fat and muscle cells, enhancing or correcting the intracellular signaling chain induced by insulin. Expression of the glucose transporter protein GLUT 1 and GLUT 4 was increased by 10 fold after Pioglitazone administration. It thus increases transcription of various proteins, amplifies post receptor action of insulin, restores glucose transportation by inhibiting gluconeogenesis and ensures effective glycaemic control in insulin resistant type 2 diabetes mellitus. It exhibits beneficial role in hypertensive patients, do not induce hypoglycaemia and reduces hyperinsulinaemia.

C O M P O S I T I O N

C O M P O S I T I O N
Piokap - 15mg Tablets Each film coated tablet contains: Pioglitazone - 15 mg
Piokap - 30mg Tablets Each film coated tablet contains: Pioglitazone - 30 mg


I N D I C AT I O N S

Piokap is indicated in Insulin resistant Type 2 diabetes mellitus.

D O S A G E

Piokap – Usual recommended is 15 mg or 30 mg once daily and maximum of 45 mg / day once.
It can be taken irrespective of meal time and no dosage titration is required in the elderly or patients with moderate renal impairment. It can be safely co-administered with Metformin, Sulphonylureas & Glucosidase inhibitors and even Insulin.

S I D E E F F E C T S

Apart from edema the following adverse events were reported – URTI, headache, sinusitis, myalgia, tooth disorder and pharyngitis.

P R E S E N TAT I O N & PACK

Piokap 15 : Tablets of 10 X 10’s blister pack..
Piokap 30 : Tablets of 10 X 10’s blister pack.

Piokap™ - MF

FOR EFFECTIVE GLYCAEMIC CONTROL & REVERSAL OF INSULIN RESISTANCE

D E S C R I P T I O N / M O D E O F A C T I O N

Piokap – MF is combination of Pioglitazone and Metformin. Pioglitazone belongs to thiazolidinedione group of oral anti-diabetic drugs, that has been developed for the treatment of type 2 diabetes mellitus. It acts by binding with high affinity to and activates the nuclear Peroxisome Proliferator Activated Receptor – Gamma (PPAR- Gamma) - expressed mainly in fat and muscle cells, enhancing or correcting the intracellular signaling chain induced by insulin. Expression of the glucose transporter protein GLUT 1 and GLUT 4 was increased by 10 fold after Pioglitazone administration. It thus increases transcription of various proteins, amplifies post receptor action of insulin, restores glucose transportation by inhibiting gluconeogenesis and ensures effective glycaemic control in insulin resistant type 2 diabetes mellitus.It exhibits beneficial role in hypertensive patients, do not induce hypoglycaemia and reduces hyperinsulinaemia. Its combination with Metformin resulted in statestically significant drop in triglyceride levels and improvement in lipid profiles by increasing the mean HDL cholesterol level.

C O M P O S I T I O N

C O M P O S I T I O N
Piokap – MF Tablets Each film coated tablet contains: Pioglitazone - 15mg + Metformin[SR] - 500mg.



I N D I C AT I O N S

Piokap – MF is indicated in Insulin resistant Type 2 diabetes mellitus and PCOD.
Piokap – MF is recommended in patients where there is inadequate control with monotherapy.

D O S A G E

Piokap – MF : Usually 1 tablet per day before breakfast. Metformin or other oral antidiabetic drug may be added depending on the glycaemic control.

S I D E E F F E C T S

Lactic acidosis, Vitamin 12 deficiency are most common. Less frequent adverse effects are oedema, URTI, headache, sinusitis, myalgia, tooth disorder and pharyngitis.

P R E S E N TAT I O N & PACK

Piokap – MF : Tablets 10 x 10’s in blister pack.

Rem-CC™

A Ready Remedy For Cough & Cold

D E S C R I P T I O N / M O D E O F A C T I O N

Rem-CC is a unique combination for cough and cold conditions. Because of the added advantage of Paracetamol, an para-aminophenol derivative as an antipyretic and helps even in febrile conditions during cough and cold. A proven mucolytic expectorant Bromhexine HCl, a synthetic derivative of adhatoda vasica, with a nasal decongestant, Phenylephrine, a sympathomimetic agent and in addition, a classical antihistamine, Chlorpheniramine Maleate H1 -receptor antagonist makes Rem-CC an excellent remedy for cough and cold.

C O M P O S I T I O N

C O M P O S I T I O N Each 5ml of Rem-CC Syrup contains Each Rem-CC Tablet contains
Bromhexine HCl 4 mg 8 mg
Phenylephrine HCl 2.5mg 5mg
Chlorpheniramine Maleate 2mg 2mg
Paracetamol 125mg 325mg


I N D I C AT I O N S

Rem-CC is indicated in cough, cold, coryza with febrile conditions.

D O S A G E

Tablet : 1 tablet 3-4 times daily
Syrup : Children 2.5 ml – 5 ml thrice daily
Adults 5 ml – 10 ml thrice daily

S I D E E F F E C T S

Rem-CC is well tolerated generally, occasional G.I. Tract irritation is observed.

P R E S E N TAT I O N & PACK

Bottle of 60 ml with measuring cup.
Box of 10x10’s tablets in blister strips.

RemCC™- XP

An Excellence in Airway Passage

D E S C R I P T I O N / M O D E O F A C T I O N

RemCC- XP is a unique combination for cough with sputum. Expectorants are drugs believed to increase bronchial secreation or reduce its viscosity, facilitating its removal by coughing.
Ambroxol is a metabolite of bromhexine having potent mucolytic & mucokinetic , capable of inducing thin copious bronchial secretion . It depolymerises mucopolysaccharides directly or indirectly by liberating lysosomal enzymes . Ambroxyl also poses anti inflammatory, anti oxidant & local anaesthetic activity.

C O M P O S I T I O N

C O M P O S I T I O N Each 5ml of RemCC XP syrup contains :
Ambroxol Hydrochloride 30mg
Terbutaline Sulphate 1.25mg
Guiaphenesin 50mg
Mentholated Syrup Base


I N D I C AT I O N S

I N D I C AT I O N S

Bronchial Asthma
Bronchitis & Bronchiectasis
Congestive conditions


D O S A G E

Syrup : Children 2.5 ml – 5 ml thrice daily
Adults 5 ml – 10 ml thrice daily

S I D E E F F E C T S

Remcc - XP is well tolerated generally, occasional G.I. Tract irritation is observed.

P R E S E N TAT I O N & PACK

Bottle of 60 ml with measuring cup.

RemCC™- LM

Life Made Easy in Allergic Rhinitis

D E S C R I P T I O N / M O D E O F A C T I O N

RemCC- LM is a unique combination useful in treatment of Allergic Rhinitis.

Levocetirizine is a second generation antihistamine that is effective in reducing sneezing and runny nose and is a mainstay therapy for allergic rhinitis. Montelukast helps in reducing symptoms of allergic rhinitis that are not controlled with antihistamines alone by competitively and reversibly inhibits cysteinyl leukotrienes (CysLTs), specifically leukotrienes D4 (LTD4), theoretically decreasing congestion and stuffiness associated with allergic rhinitis and in comparison to antihistamines appear to have significantly better improvement in night time symptoms

C O M P O S I T I O N

C O M P O S I T I O N Each tablet of RemCC LM contains : Each 5 ml of Rem CC LM syrup contains :
Levocetirizine Hydrochloride 5mg 2.5mg
Montelukast Sodium 10mg 4mg


I N D I C AT I O N S

I N D I C AT I O N S
Seasonal Allergic Rhinitis
Perennial Allergic Rhinitis
Asthmatic conditions


D O S A G E

Tablets:
Adults : 1 tablet once daily (at evening)

Syrup : Children (6 – 14 years): 1 tsp once daily (at evening)
Children (2 – 6years) : ˝ tsp once daily (at evening)

S I D E E F F E C T S

Most common adverse reactions (incidence ≥5%) reported with Montelukast are upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis.

The most common adverse reactions reported with Levocetirizine (rate ≥2%) were somnolence, nasopharyngitis, fatigue, dry mouth, and pharyngitis in subjects 12 years of age and older, pyrexia, somnolence, cough, and epistaxis in children 6 to 12 years of age and pyrexia, diarrhea, vomiting, and otitis media in subjects 1 to 5 years of age. In children 6 to 11 months of age, the most common adverse reactions (rate ≥3%) were diarrhea and constipation.

P R E S E N TAT I O N & PACK

Syrup : Bottle of 30 ml with measuring cup in a carton.
Tablets : Box of 10x10’s tablets in blister strips.

TOPRAZOL™

A step above the conventional management of Acid Peptic Diseases

D E S C R I P T I O N / M O D E O F A C T I O N

Toprazol (Pantoprazole) is a pyridyl methylsulfinyl benzimidazole, which causes irreversible inhibition of proton pump (H+ K+ -AT Pase) function. Pantoprazole after absorption from the upper intestine enters the blood stream. From here it enters the parietal cell, crosses the cell membrane and gets concentrated in the canaliculi. In the canaliculi, because of the strong acidic condition it gets converted to sulphenamide derivatives. The sulphinamide derivatives of pantoprazole inactivate the sulfhydryl group of H+ K+ Adenosine Tri-Phosphatase ( A T Pase), which in turn catalyses the final step of the gastric acid secretion pathway, thus inhibiting both centrally and peripherally mediated gastric acid secretion. It is rapidly activated under strongly acidic conditions. This pH dependent activation profile underlines the in-vitro selectivity of pantoprazole against H+ K+ AT Pase compared with Omeprazole. Pantoprazole is rapidly absorbed after oral administration with peak plasma concentration of 1.1 to 3.1 mg / L (Cmax) occuring 2 to 4 hours (Tmax) after ingestion of an enteric coated 40 mg tablet. The drug is subject to low hepatic extraction, displaying an estimated absolute bioavailability of 77%. Elimination half-life of Pantoprazole is 0.9 to 9 hours. However inhibition of acid secretion, once accomplished, persists long after the drug has been cleared from the circulation and has a plasma protein binding of 98%. Pantoprazole undergoes extensive hepatic metabolism via cytochrome p 450 mediated oxidation followed by sulphate conjugation. Elimination is predominantly renal with 80% of an oral or intravenous dose being excreted as urinary metabolites, the remainder is excreted in the faeces and originates primarily from biliary secretion.

C O M P O S I T I O N

C O M P O S I T I O N Each tablet of Toprazol contains :
Pantoprazole 40mg


I N D I C AT I O N S

v
I N D I C AT I O N S Pantoprazole is indicated for the treatment of acid related disorders like :
Gastric and duodenal ulcers Reflux Oesophagitis
Zollinger-Ellison syndrome For the eradication of H. Pylori, it can be combined with other antibacterial agents
Treatment of ulcers resistant to H2 antagonists Maintenance of ulcer remission
Treatment of ulcers induced by NSAIDs Treatment of non ulcer dyspepsia

D O S A G E

It is given orally in a dose of 40 mg once daily before breakfast. Dosage adjustment is not required in the elderly and in patients with renal impairment or in those with hepatic impairment.

S I D E E F F E C T S

On short term administration, the most common adverse reported with the drug include:
vDiarrhoea (1.5%)
vDiziness (0.7%)
vPruritis (0.06%)
vSkin rash (0.4%)
These are generally mild or of moderate intensity, rarely necessitating treatment withdrawal.

P R E S E N TAT I O N & PACK

Toprazol tablet is available in blister pack of 10 x 10’s.

TOPRAZOL™- D

The Complementary Duo for prompt Ulcer Healing

D E S C R I P T I O N / M O D E O F A C T I O N

Pantoprazole is a pyridyl methylsulfinyl benzimidazole, which causes irreversible inhibition of proton pump (H+ K+ -AT Pase) function. Pantoprazole after absorption from the upper intestine enters the blood stream. From here it enters the parietal cell, crosses the cell membrane and gets concentrated in the canaliculi. In the canaliculi, because of the strong acidic condition it gets converted to sulphenamide derivatives. The sulphinamide derivatives of pantoprazole inactivate the sulfhydryl group of H+ K+ Adenosine Tri-Phosphatase ( A T Pase), which in turn catalyses the final step of the gastric acid secretion pathway, thus inhibiting both centrally and peripherally mediated gastric acid secretion. It is rapidly activated under strongly acidic conditions. This pH dependent activation profile underlines the in-vitro selectivity of pantoprazole against H+ K+ AT Pase compared with Omeprazole.

Domperidone is a dopamine antagonist acts centrally by inhibiting dopamine receptors at CTZ and peripherally acts on G.I. tract, by increasing Lower Esophageal Spincter (LES) pressure by enhancing gastric contractions and relaxing the pyloric sphincter pressure. It blocks oesophageal reflux by ensuring prompt prokinesis and increasing LES pressure

C O M P O S I T I O N

C O M P O S I T I O N Each capsule of Toprazol D contains:
Pantoprazole (EC) 40mg
Domperidone (SR) 30mg


I N D I C AT I O N S

I N D I C AT I O N S
Pantoprazole is indicated for the treatment of acid related disorders like :
Gastric and duodenal ulcers
Gastro Esophageal Reflux Disease (GERD)
Non ulcer dypepsia


D O S A G E

It is given orally in a dose of one capsule once daily about half an hour before breakfast. Pantoprazole is not recommended for children less than 12years. Caution should be exercised in patients with history of liver disease, any other gastrointestinal disorders, any allergy and during pregnancy. Avoid prolonged usage of this medication. It may cause dizziness, do not drive a car or operate machinery while taking this medication. Domperidone products are now contraindicated in patients with severe hepatic impairment, conditions where the cardiac conduction intervals are impaired or could be affected and underlying cardiac diseases as congestive heart failure, when co-administered with QT-prolonging drugs or potent CYP3A4 inhibitors.

S I D E E F F E C T S

Pantoprazole: Headache (>4%), Abdominal pain (4%), Facial edema (<4%), Generalized edema (<2%), Chest pain (4%), Diarrhea (4%), Constipation (<4%), Pruritus (4%), Rash (4%), Flatulence (<4%), Hyperglycemia (1%), Nausea (1%), Vomiting (>4%), Photosensitivity (<2%)
Domperidone: Usually peripheral dopaminergic side effects like dry mouth, diarrhoea and very rearely galactorrhoea and gynaecomastia have been observed. Recent review identified a small increased risk of serious cardiac adverse drug reactions related to the use of domperidone. especially in patients older than 60 years, those taking daily doses of more than 30 mg, and those taking QT-prolonging drugs or CYP3A4 inhibitors concomitantly.

P R E S E N TAT I O N & PACK

Toprazol D capsules are available in blister pack of 10 x 10’s.

Vast™

An unique ayurvedic cough syrup

D E S C R I P T I O N / M O D E O F A C T I O N

Vast is an ayurvedic cough syrup with unique combination of cough ingredients. Vast abates cough quickly and provides soothing effect reducing throat and bronchial irritation. Vast has a broad spectrum activity which relieves cough of varied aetiology. Vast relieves bronchial congestion and reduces susceptibility to cough by increasing resistance.

C O M P O S I T I O N

C O M P O S I T I O N
Each 5ml of Vast contains extracts equivalent to : Qty in mg.
Ocimum sanctum (Tulasi) 100
Adhatoda vasika (Vasaka) 50
Sida cordifolia (Bala) 20
Inula racemosa (Pushkaramoola) 50
Glycyrrhiza glabra (Yashtimadhu) 50
Zingiber officinale (Sringavera / Shunti) 15
Piper longum (Pippali) 15
Albizzia lebbeck (Shirisha) 50
Navasara 80


I N D I C AT I O N S

Vast is indicated in cough, allergic bronchitis, tracheitis, bronchiolitis

D O S A G E

Adult – 10 ml tid
Children - 2.5 ml – 5 ml tid

S I D E E F F E C T S

No untoward side effects are noticed.

P R E S E N TAT I O N & PACK

Bottle of 100 ml

VITALPHA - C™

The Vital Supplement In Osteopenic Fragility

D E S C R I P T I O N / M O D E O F A C T I O N

Vitalpha (Alfacalcidol) is an analogue of calciol (cholecalciferol, vitamin D3 ) which is hydroxylated to calcitriol (1,25 dihydroxy cholecalciferol, 1,25-(OH)2 vitamin D3 ), the most potent natural metabolite of calciol. Alfacalcidol is fat soluble and absorbed upto 100%. After absorption, Alfacalcidol is rapidly hydroxylated at the 25 th position, predominantly in the liver. After hydroxylation Alfacalcidol is converted to 1,25 dihydroxy cholecalciferol [1,25 dihydroxy vit. D3 , calcitriol]. By virtue of its high solubility in the lipids, Alfacalcidol is rapidly distributed throughout the body and appear in plasma within 30 minutes. Plasma half-life is 3 hours. 13% gets excreted through urine, 5% through faeces and the balance as other metabolites. Vitalpha – C is a combination of Alfacalcidol with Elemental Calcium recommended in osteoporotic patients with low dietary calcium intake.

C O M P O S I T I O N

C O M P O S I T I O N Each Soft Gelatin Capsule of Vitalpha – C contains:
Alfacalcidol (1-alpha hydroxy vitamin D3) 0.25mcg
Elemental Calcium 250mg


I N D I C A T I O N S

I N D I C AT I O N S
Alfacalcidol is indicated for the treatment of diseases caused by disturbances in calcium metabolism as a consequence of reduced endogenous production of 1,25 (OH)2 D3 a fortified vital therapy indicated in Glucocorticoid induced/diabetic/senile/postmenopausal osteoporotic cases
Osteoporosis Renal osteodystrophy
Neonatal hypocalcaemia Vitamin D dependent rickets
Rickets in premature infants Hypocalcaemia in hypoparathyroidism
Osteomalacia due to malabsorption syndrome Hypocalcaemia & hypomagnesaemia after small bowel resection
Hypocalcaemia and parathyroid bone disease after parathyroidectomy Drug induced osteoporosis


D O S A G E

VITALPHA – C : One to four capsules per day in single dose depending on the condition and response. Periodic monitoring of plasma calcium level and dose alteration accordingly is suggested.

S I D E E F F E C T S

Alfacalcidol has a low therapeutic index and possible adverse effects can be hypercalcaemia, hyperphosphataemia or hypermagnesaemia. Alfacalcidol, should not be used in patients with evidence of Vitamin D toxicity or known hyper sensitivity to the effects of Vitamin D or any of its analogues.

P R E S E N TAT I O N & PACK

Vitalpha-C is available in soft gelatin capsules in blister strips of 10 X 10s.

VITATROL™- PLUS

The Vital Bone Matrix Optimizer

D E S C R I P T I O N / M O D E O F A C T I O N

Vitatrol plus contains Calcitriol, Calcium Carbonate and Zinc Sulphate.
Calcitriol - Most active form of vitamin D. Calcitriol regulates calcium homoeostasis and helps maintain normal calcium and phosphorus levels in the plasma and bone. . The plasma calcium level is increased by increased absorption of calcium from the gut and by decreasing renal calcium excretion. Independent of the above action calcitriol enhances bone mineralisation.
Calcium Carbonate - Is present in all tissues of the body the major portion is found in the bones. In fact the bones act like calcium reservoir. Dietary deficiency of calcium is thought to play a significant role in the development of osteoporosis.

Zinc - Bone growth retardation is a common finding in various conditions associated with zinc deficiency. Zinc has been demonstrated to have stimulatory effect on bone formation and mineralisation. Zinc directly activates aminoacyl – t RNA synthesis in osteoblastic cells and improves protein synthesis. It also inhibits osteoclastic bone resorption by inhibiting osteoclast formation from the bone marrow.

C O M P O S I T I O N

C O M P O S I T I O N Each softgel Capsule contains :
Calcitriol 0.25mcg
Elemental Calcium 250mg
Zinc Sulphate 7.5mg


I N D I C AT I O N S

I N D I C AT I O N S
Postmenopausal osteoporosis
Senile osteoporosis
Corticosteroid induced osteoporosis


D O S A G E

The recommended dosage is one capsule twice daily. Serum Calcium levels are monitored frequently.

C O N T R A I N D I C A T I O N S

Hypersensitivity to any of the ingredients
Hypocalcaemia

P R E S E N TAT I O N & PACK

Vitatrol Plus is available in soft gelatin capsules in blister strips of 10 X 10’s.

VERPENEM™

An ACE among Antibacterials

D E S C R I P T I O N / M O D E O F A C T I O N

Verpenem belongs to Carbapenems
vStructure -Addition of methyl group in 1-position of the carbapenem moiety
vCell wall synthesis inhibitor
vActive against - Gram positive, Gram negative
vAnaerobic
vSensitive even to organisms producing - Beta- lactamase, Pencillinase, MRSA
Klebsiella pneumoniae, Enterobacter cloacae, Pseudomonas aeruginosa, Acinetobacter baumannii, Haemophilus influenzae, Bacteroides fragilis.
vESBL producing pathogens
Half life - 1h, Protein binding- 2-10%
Not hydrolysed by DHP-1

C O M P O S I T I O N

C O M P O S I T I O N
Verpenem 500mg Inj Each Vial contains : Meropenem - 500 mg
Verpenem 1gm Inj Each Vial contains : Meropenem - 1 gm
.

I N D I C AT I O N S

I N D I C AT I O N S
Bacterial meningitis [Bacteriological cure rate – 97%]

Febrile neutropenia
Lower respiratory infections Cystic fibrosis - 98%
Nosocomial pneumonia - 91% Community acquired pneumonia – near 100%
Complicated Skin & Soft Tissue injuries- cSSTIs Surgical wound

Severe diabetic foot infections Burns

Septicaemia, septic shock

Complicated Urinary Tract Infection
Gynaecological infection Genito-urinary tract infection


D O S A G E

Dose (mg)- 500-2000 mg (10 to 40 mg/kg) by slow intravenous injection 8th hourly

S I D E E F F E C T S

Less renal toxic
Seizure rate of 0.08%
GI Adverse effects- low at 1.4%

P R E S E N TAT I O N & PACK

Meropenem – 1 gm & 500 mg Vials with Distilled Water & Tray.

VERIXIME™

Versatile Strike Against All Infections

D E S C R I P T I O N / M O D E O F A C T I O N

Cefixime belongs to third generation Cephalosporins
vBactericidal antibiotic - Cell wall synthesis inhibitor
vActive against Gram positive, Gram negative
vSensitive even to organisms producing - Beta- lactamase
vKlebsiella pneumoniae,Enterobacter cloacae, Moraxella catarrhalis, Acinetobacter baumannii, Neisseria gonorrhoeae, Haemophilus influenzae, Bacteroides fragilis.
vESBL producing pathogens
vOral absorption 40- 50%,Peak plasma concentration – 2-3micro gram/ml, Half life – 3-4h
vProtein binding- 65%
vNot hydrolysed by DHP-1

C O M P O S I T I O N

C O M P O S I T I O N
Verixime-DT Each Dispersible Tablet contains : Cefixime 100mg
Verixime 200 tablet Each Dispersible Tablet contains : Cefixime 200mg
Verixime Dry Syp Each 5ml contains : Cefixime 50mg


I N D I C AT I O N S

vGonorrhea
vOtitis media
vPharngitis
vLRTI- bronchitis
vUTI
vEnteric fever
vBiliary infection

D O S A G E

Adults – 400mg daily as single dose/ in 2 divided doses
Children – 8mg/kg/ day once daily or in 2 divided doses

S I D E E F F E C T S

GI Adverse effects- diarrhea, stool changes
Hypoprothrombinaemia

P R E S E N TAT I O N & PACK

Verixime-DT- 3x10’s Blister pack
Verixime- 200- 3x10’s Blister pack
Verixime Dry syrup – 30ml with Carton

VERCLAV™

The Bacterial Claw Against Microbes

D E S C R I P T I O N / M O D E O F A C T I O N

Verclav is a combination of Amoxicillin and clavulanic acid. Amoxicillin: This drug, penicillinase-susceptible semi-synethetic penicillin, is a close chemical and pharmacological relative of ampicillin. Aminopenicillins are bactericidal for both gram-positive and gram-negative bacteria. The meningococci and L. monocytogenes are sensitive to the drug. Most strains of Shigella are now resistant. Most strains of Pseudomonas, Klebsiella, Serratia Acinetobacter, and indole positive Proteus also are resistant to this group of penicillin. However, concurrent administration of a beta-lactamase inhibitor such as clavulanate or sulbactam markedly expands the spectrum of activity of these drugs.
Clavulanic acid has poor intrinsic antimicrobial action, (by itself it cannot kill the bacteria) but it is a ‘suicide’ inhibitor. It combines irreversibly with Beta lactamase enzyme rendering the enzyme inactive. This inactivated enzyme is unable to destroy Beta lactamase antibiotics (penicillins and cephalosporins). Thus a resistant organism becomes susceptible to the action of antibiotics.

C O M P O S I T I O N

C O M P O S I T I O N
Verclav 625mg Tablets Each Tablet contains : Amoxycillin-500mg + Clavulanate Potassium-125mg
Verclav 375mg Tablets Each Tablet contains : Amoxycillin-250mg + Clavulanate Potassium-125mg
Verclav Dry Syrup Each 5ml contains : Amoxycillin-200mg + Clavulanate Potassium-28.5mg
Verclav 1.2gm Inj Each Vial contains : Amoxycillin-1gm + Clavulanate Potassium-200mg
Verclav 600mg Inj Each Vial contains : Amoxycillin-500mg + Clavulanate Potassium-100mg
Verclav 300mg Inj Each Vial contains : Amoxycillin-250mg + Clavulanate Potassium-50mg


I N D I C AT I O N S

I N D I C AT I O N S
Bacterial meningitis Peritonitis
Post-operative infections Genito-urinary infections
LRTI- Bronchitis Urinary Tract infections
Skin & soft tissue infection Enteric fever


D O S A G E

Adults- 250-500 mg every 8hr/ 500-750 mg every 12 hr
Children – 125-250 mg every 8 hr, if less than <40 kg: 20-40 mg/kg/day

S I D E E F F E C T S

GI Adverse effects- diarrhea, Candidiasis, antibiotic-associated colitis
Hypersensitivity reactions
Skin rash, (urticarial and erythematous) sometimes occurs.
Rarely erythema multiforme,
Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous exfoliative dermatitis and acute generalised exanthematous opustulosis

C O N T R A I N D I C A T I O N S

Penicillin hypersensitivity.
Attention should be paid to possible cross-sensitivity with other beta-lactam antibiotics, e.g. Cephalosporins.
A previous history of Clavulanate Potassium and Amoxycillin Injection or Penicillin associated jaundice/hepatic dysfunction

P R E S E N TAT I O N & PACK

Verclav 375 mgTab- 10x10 Alu Alu pack
Verclav 625 mgTab – 10x10 Alu Alu pack
Verclav Dry Syrup – 30ml with Carton
Verclav inj – 300mg / 600mg / 1.2gm

Zinfe – SR™

A haematinic with Zinc and Vitamins

D E S C R I P T I O N / M O D E O F A C T I O N

Zinfe – SR is a sustained release haematinic with Zinc, specially formulated for the expectant mother, which ensures maternal and foetal care. Besides combining Iron & Zinc, Zinfe – SR incorporates other complimentary factors for haemopoiesis viz. Vitamin B12, Vitamin B 6, and Folic acid. Zinfe – SR is designed to provide therapeutic supplement in pregnancy anaemia and also in general anaemia arising out of parasitic infestations, blood loss, haemorrhoids etc.

C O M P O S I T I O N

C O M P O S I T I O N Each sustained release capsule contains :
Ferrous sulphate 150 mg
Zinc sulphate 61.8 mg
Folic acid 1.5 mg
Vitamin B 12 15 mcg
Vitamin B 6 3 mg


I N D I C AT I O N S

Zinfe – SR is indicated in pregnancy anaemia, nutritional anaemia, parasitic anaemia, Zinc deficiency and in post operative cases as a supplement.

D O S A G E

One to two capsule / day during pregnancy related anaemia.
One capsule twice daily during severe anaemic conditions.

S I D E E F F E C T S

Hyper sensitivity to Zinfe – SR is rare. Tetracycline should not be combined with Zinfe – SR. It is advisable to avoid taking Zinfe – SR with hot water and to avoid using in renal failure. Zinc is known to interact with Fluroquinolines and Penicillamine reduces absorption. Adverse effects though rare, are nausea, vomiting and abdominal pain.

P R E S E N TAT I O N & PACK

Strips of 10 X 10’s sustained release capsules in blister pack.

Zinfe™ – XT & Syp

The Naturally Rich Iron For Generation NeXT

D E S C R I P T I O N / M O D E O F A C T I O N

Zinfe – XT & Syp are for Premium Class of Generation NeXT Women. Pregnancy is a Natural Phenomena and Pregnancy Care is even more important to be taken care Naturally. The Iron in Zinfe – XT & Syp is as present in Nature like in Spinach. Ferrous Bisglycinate offers a Natural Iron having a very high bioavailability and a better increase in Hb level. The advantages of the composition of Ferrous Bisglycinate, Zinc Bisglycinate, Folic Acid and with the benefits of Vitamin B12 altogether are;
v Bis Glycinate Chelates prevent binding & precipitation of Iron
v Zinc improves immune system
v Folic Acid & Vitamin B12 helps synthesis of DNA.

Iron amino-acid chelates are conjugates of the ferrous or ferric ion with amino-acids. Although numerous conjugates have been formulated the most studied of these are ferrous bis-glycinate (20% elemental iron content), ferric trisglycinate and ferrous glycine sulphate. Their main advantage lies in their relatively high bioavailability in the presence of dietary inhibitors. It is theorized that the chelates prevent iron from binding to inhibitors in food or precipitating as insoluble ferric hydroxide in the pH of the small intestine. In a study, in infants the absorption of iron from ferrous bis-glycinate was found to be equivalent to that of Ferrous Sulphate-ascorbic acid combination. A recent study in adults has also demonstrated good absorption of Ferrous Bisglycinate (5-6 times higher) in the presence of phytates from maize.

C O M P O S I T I O N

Composition Per Tab Per 5 ml Syp
Ferrous Bisglycinate
Equivalent to elemental Iron
60 mg 15 mg
Zinc Bisglycinate
Equivalent to elemental Zinc
15 mg 5.5 mg
Folic Acid 1 mg 0.25 mg
Vitamin B12 15 mcg 3.75 mcg


I N D I C AT I O N S

Zinfe – XT & Syp are indicated in pregnancy anaemia, nutritional anaemia, parasitic anaemia, Zinc deficiency and in post operative cases as a supplement.

D O S A G E

One Tablet once or twice daily or 2 Teaspoonful once or twice daily
Children : More than 2 months to 12 years - 1 Teaspoonful once or twice daily

P R E S E N TAT I O N & PACK

Tablets of 3 x 10’s Strips in blister pack & Syrup in 150ml in an attractive pack.


© 2003 Karnataka Antibiotics & Pharmaceuticals Limited. All rights reserved. Developed by SIFY Limited.